Topics

Interview: AstraZeneca ‘Is More Than Oncology’

10:12 EDT 28 Oct 2019 | SCRIP

Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this...

      

Related Stories

 

Original Article: Interview: AstraZeneca ‘Is More Than Oncology’

NEXT ARTICLE

More From BioPortfolio on "Interview: AstraZeneca ‘Is More Than Oncology’"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...